How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/maintenance-therapy-of-unresectable-urothelial-carcinoma-in-patients-who-have-received-chemotherapy.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Maintenance therapy of unresectable urothelial carcinoma in patients who have received chemotherapy — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Maintenance therapy of unresectable urothelial carcinoma in patients who have received chemotherapy (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Maintenance therapy of unresectable urothelial carcinoma in patients who have received chemotherapy, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Bavencio	avelumab	Merck KGaA	Programmed Death Ligand-1 Blocker [EPC]	Programmed cell death 1 ligand 1		2017-01-01
Bavencio	Bavencio	Pfizer		Programmed cell death 1 ligand 1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Merck KGaA · 1 drug in Maintenance therapy of unresectable urothelial carcinoma in patients who have received chemotherapy
Pfizer · 1 drug in Maintenance therapy of unresectable urothelial carcinoma in patients who have received chemotherapy

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Maintenance therapy of unresectable urothelial carcinoma in patients who have received chemotherapy:

Cite this brief

Drug Landscape (2026). Maintenance therapy of unresectable urothelial carcinoma in patients who have received chemotherapy — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/maintenance-therapy-of-unresectable-urothelial-carcinoma-in-patients-who-have-received-chemotherapy. Accessed 2026-06-10.

Maintenance therapy of unresectable urothelial carcinoma in patients who have received chemotherapy full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing